Skip to main content
Premium Trial:

Request an Annual Quote

Beckman Shares Drop 8.8 Percent

Following the release late last week of disappointing fourth-quarter results (see feature), shares in Beckman Coulter dropped 8.8 percent for the tracking period ended Tuesday. Beckman posted the largest decline of any of the eight firms in the BCW Index that posted a loss for the four-day trading week. Molecular Devices led the eight gainers with a 6.9-percent spike in its share price.

Overall, the Index fell .3 percent. For the week, the Dow Jones Industrial Average rose .4 percent, the Nasdaq was flat, and the Nasdaq Biotech Index rose 2.1 percent.

BioCommerce Week Index of Diversified Molecular Biology Tool Companies
Company
Ticker
Current Price
(Feb. 21, 2006)
Last Price
(Feb. 14, 2006)
% change
Agilent
A
35.14
34.8
0.98
Applied Biosystems
ABI
28.68
28.29
1.38
Beckman
BEC
54.8
60.11
-8.83
Bio-Rad
BIO
65.07
65.67
-0.91
Bruker
BRKR
4.57
4.58
-0.22
Fisher Scientific
FSH
67.5
68.5
-1.46
GE
GE
33.36
33.46
-0.30
Harvard Bio
HBIO
5.0
4.78
4.60
Invitrogen
IVGN
67.69
66.0
2.56
Molecular Devices
MDCC
32.45
30.35
6.92
PerkinElmer
PKI
23.61
23.2
1.77
Qiagen
QGEN
13.76
13.18
4.40
Sigma
SIAL
64.48
64.34
0.22
Stratagene
STGN
10.2
10.65
-4.23
Thermo
TMO
33.86
34.43
-1.66
Waters
WAT
42.28
42.06
0.52
BCW Index Average
36.40
36.53
-0.33
The Scan

For Better Odds

Bloomberg reports that a child has been born following polygenic risk score screening as an embryo.

Booster Decision Expected

The New York Times reports the US Food and Drug Administration is expected to authorize a booster dose of the Pfizer-BioNTech SARS-CoV-2 vaccine this week for individuals over 65 or at high risk.

Snipping HIV Out

The Philadelphia Inquirer reports Temple University researchers are to test a gene-editing approach for treating HIV.

PLOS Papers on Cancer Risk Scores, Typhoid Fever in Colombia, Streptococcus Protection

In PLOS this week: application of cancer polygenic risk scores across ancestries, genetic diversity of typhoid fever-causing Salmonella, and more.